{"status": "ok", "totalResults": 4, "articles": [{"source": {"id": null, "name": "BBC News"}, "author": null, "title": "Telegraph up for sale after takeover collapses - BBC.com", "description": "The ownership of the Daily and Sunday Telegraph was set to be transferred to a Abu Dhabi-backed bid.", "url": "https://www.bbc.com/news/business-68926764", "urlToImage": "https://ichef.bbci.co.uk/news/1024/branded_news/11738/production/_132208417_gettyimages-1258536790.jpg", "publishedAt": "2024-04-30T11:19:22Z", "content": null}, {"source": {"id": null, "name": "CoinDesk"}, "author": "Sam Reynolds", "title": "Hong Kong Bitcoin and Ether ETFs Have Soft Debut - CoinDesk", "description": "The volume of crypto exchange-traded funds came in at just over $11 million.", "url": "https://www.coindesk.com/markets/2024/04/30/hong-kong-bitcoin-and-ether-etfs-have-soft-debut/", "urlToImage": "https://www.coindesk.com/resizer/AcbVcB4hgSK5T8oWVJtTuXPTnws=/1200x628/center/middle/cloudfront-us-east-1.images.arcpublishing.com/coindesk/YJKVVHZBQ5FXTPRG3VLYIHZ3JQ.jpg", "publishedAt": "2024-04-30T08:50:00Z", "content": "Please note that ourprivacy policy,terms of use,cookies, anddo not sell my personal informationhas been updated.\r\nCoinDesk is anaward-winningmedia outlet that covers the cryptocurrency industry. Its \u2026 [+593 chars]"}, {"source": {"id": null, "name": "Ses.com"}, "author": null, "title": "SES to acquire Intelsat in compelling transaction focused on the future - SES | Satellite", "description": "Value accretive transaction underpinned by \u20ac2.4 billion (NPV) of readily executable synergies.", "url": "https://www.ses.com/press-release/ses-acquire-intelsat-compelling-transaction-focused-future", "urlToImage": null, "publishedAt": "2024-04-30T03:06:22Z", "content": "<ul><li>Value accretive transaction underpinned by 2.4 billion (NPV) of readily executable synergies.</li><li>Creating a stronger multi-orbit operator with ~60% of revenue in high growth segments.</l\u2026 [+17011 chars]"}, {"source": {"id": null, "name": "Astrazeneca.com"}, "author": null, "title": "Enhertu demonstrated statistically significant and clinically meaningful improvement in progression-free survival in HR-positive, HER2-low metastatic breast cancer following one or more lines of endocrine therapy in DESTINY-Breast06 Phase III trial - AstraZeneca", "description": "", "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/enhertu-improved-pfs-in-her2-low-and-ultralow.html", "urlToImage": "", "publishedAt": "2024-04-29T01:30:00Z", "content": "Positive high-level results from the DESTINY-Breast06 Phase III trial showed that Enhertu (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in pr\u2026 [+12518 chars]"}]}